Phase 2, double-blind, placebo-controlled study to evaluate the effectiveness of two doses of AP-472 as adjunctive therapy to levodopa in Parkinson's disease (PD) participants with motor fluctuations
Not yet recruiting
This is a Phase 2 study in people with Parkinson's disease who experience motor fluctuations while taking levodopa. The study will evaluate how effective two different doses of the study drug AP-472 are when added to levodopa treatment, compared with a placebo.
The study will la…
Phase: PHASE2 • Sponsor: Appello Pharmaceuticals, Inc.
Last updated Mar 02, 2026 15:25 UTC